E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia
Preetesh Jain,Hagop M. Kantarjian,Farhad Ravandi,Elias Jabbour,Naval Daver,Naveen Pemmaraju,Courtney D. DiNardo,Yesid Alvarado,Nitin Jain,Gautam Borthakur,Srdan Verstovsek,Alessandra Ferrajoli,Maro Ohanian,Marina Konopleva,Kiran Naqvi,Tina Fitch,Guillermo Garcia-Manero,Jorge E. Cortes,Zeev Estrov,Tapan M. Kadia +19 more
TL;DR: This study investigated a higher dose of araC in combination with cladribine and idarubicin in younger patients with AML, and reported promising results that exceeded pretreatment expectations for response and tolerability.
Journal ArticleDOI
Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
TL;DR: Research is ongoing to optimize the benefit of targeted therapeutics with the goal of decreasing the use of cytotoxic therapies.
Journal ArticleDOI
Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study
Nicholas J. Short,Hagop M. Kantarjian,Farhad Ravandi,Xuelin Huang,Nitin Jain,Tapan M. Kadia,Joseph D. Khoury,Jeffrey L. Jorgensen,Sa A. Wang,Yesid Alvarado,Jan A. Burger,Naval Daver,Gautam Borthakur,Courtney D. DiNardo,Marina Konopleva,Naveen Pemmaraju,Guillermo Garcia-Manero,William G. Wierda,Steven M. Kornblau,Jovitta Jacob,Meagan Rostykus,Monica Kwari,Caitlin R. Rausch,Christopher Loiselle,Anna Milton,Juan Rivera,Rebecca Garris,Susan O'Brien,Elias Jabbour +28 more
TL;DR: Use of these effective monoclonal antibodies in the frontline setting may lead to deep and durable remissions in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell ALL.
Journal ArticleDOI
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimens
Rashmi Kanagal-Shamanna,Preetesh Jain,Koichi Takahashi,Nicholas J. Short,Guilin Tang,Ghayas C. Issa,Farhad Ravandi,Guillermo Garcia-Manero,Cameron C. Yin,Rajyalakshmi Luthra,Keyur P. Patel,Joseph D. Khoury,Guillermo Montalban-Bravo,Koji Sasaki,Tapan M. Kadia,Gautam Borthakur,Marina Konopleva,Nitin Jain,Rebecca Garris,Sherry Pierce,William G. Wierda,Zeev Estrov,Jorge E. Cortes,Susan O'Brien,Hagop M. Kantarjian,Elias Jabbour +25 more
TL;DR: Tumor protein 53 (TP53) mutations are uncommon in adult patients with acute lymphoblastic leukemia (ALL) and predict a poor outcome.
Journal ArticleDOI
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy.
Koji Sasaki,Tapan M. Kadia,Kebede H. Begna,Courtney D. DiNardo,Gautam Borthakur,Nicholas J. Short,Nitin Jain,Naval Daver,Elias Jabbour,Guillermo Garcia-Manero,Guillermo Montalban Bravo,Lucia Masarova,Sherry Pierce,Marina Konopleva,Farhad Ravandi,Ayalew Tefferi,Hagop M. Kantarjian +16 more
TL;DR: In this paper, the authors reviewed the outcome of 3728 patients with newly diagnosed acute myeloid leukemia (AML) who received intensive chemotherapy between August 1980 and May 2020, and divided the whole cohort into a training and validation group at a 3:1 ratio.